Private Advisor Group LLC Has $346,000 Holdings in Natera, Inc. (NASDAQ:NTRA)

Private Advisor Group LLC lifted its holdings in shares of Natera, Inc. (NASDAQ:NTRA) by 5.2% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 2,721 shares of the medical research company’s stock after purchasing an additional 135 shares during the period. Private Advisor Group LLC’s holdings in Natera were worth $346,000 as of its most recent filing with the SEC.

A number of other hedge funds also recently modified their holdings of the business. Vanguard Group Inc. lifted its holdings in shares of Natera by 0.7% during the first quarter. Vanguard Group Inc. now owns 11,044,743 shares of the medical research company’s stock worth $1,010,152,000 after purchasing an additional 72,848 shares during the period. Farallon Capital Management LLC lifted its holdings in shares of Natera by 13.6% during the second quarter. Farallon Capital Management LLC now owns 4,460,557 shares of the medical research company’s stock worth $483,034,000 after purchasing an additional 532,874 shares during the period. Massachusetts Financial Services Co. MA lifted its holdings in shares of Natera by 6.6% during the second quarter. Massachusetts Financial Services Co. MA now owns 2,397,582 shares of the medical research company’s stock worth $259,634,000 after purchasing an additional 148,917 shares during the period. Duquesne Family Office LLC lifted its holdings in shares of Natera by 2.4% during the second quarter. Duquesne Family Office LLC now owns 1,974,880 shares of the medical research company’s stock worth $213,860,000 after purchasing an additional 45,500 shares during the period. Finally, Allspring Global Investments Holdings LLC lifted its holdings in shares of Natera by 25.0% during the third quarter. Allspring Global Investments Holdings LLC now owns 1,229,558 shares of the medical research company’s stock worth $156,092,000 after purchasing an additional 246,246 shares during the period. Institutional investors and hedge funds own 99.90% of the company’s stock.

Insider Transactions at Natera

In other news, CFO Michael Burkes Brophy sold 1,866 shares of the business’s stock in a transaction dated Thursday, October 31st. The shares were sold at an average price of $126.45, for a total transaction of $235,955.70. Following the completion of the sale, the chief financial officer now directly owns 68,851 shares of the company’s stock, valued at $8,706,208.95. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. In other news, CFO Michael Burkes Brophy sold 1,866 shares of the business’s stock in a transaction dated Thursday, October 31st. The shares were sold at an average price of $126.45, for a total transaction of $235,955.70. Following the completion of the sale, the chief financial officer now directly owns 68,851 shares of the company’s stock, valued at $8,706,208.95. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Jonathan Sheena sold 2,700 shares of the business’s stock in a transaction dated Monday, August 12th. The stock was sold at an average price of $113.82, for a total transaction of $307,314.00. Following the sale, the insider now directly owns 299,441 shares of the company’s stock, valued at approximately $34,082,374.62. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 50,164 shares of company stock valued at $6,157,291 over the last three months. Corporate insiders own 7.60% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on the stock. Canaccord Genuity Group lifted their price target on shares of Natera from $145.00 to $150.00 and gave the stock a “buy” rating in a report on Tuesday, October 29th. Robert W. Baird boosted their target price on shares of Natera from $117.00 to $120.00 and gave the company an “outperform” rating in a report on Friday, August 9th. Sanford C. Bernstein boosted their target price on shares of Natera from $125.00 to $135.00 and gave the company an “outperform” rating in a report on Wednesday, October 30th. BTIG Research boosted their target price on shares of Natera from $125.00 to $135.00 and gave the company a “buy” rating in a report on Friday, August 9th. Finally, TD Cowen boosted their target price on shares of Natera from $137.00 to $145.00 and gave the company a “buy” rating in a report on Friday, August 9th. One investment analyst has rated the stock with a hold rating and sixteen have given a buy rating to the stock. According to MarketBeat, Natera presently has a consensus rating of “Moderate Buy” and a consensus price target of $125.69.

Natera Trading Up 0.8 %

NTRA opened at $124.39 on Wednesday. Natera, Inc. has a 1-year low of $40.61 and a 1-year high of $133.54. The company has a current ratio of 4.14, a quick ratio of 4.01 and a debt-to-equity ratio of 0.34. The company has a market cap of $15.38 billion, a P/E ratio of -50.77 and a beta of 1.53. The company has a fifty day moving average price of $123.59 and a two-hundred day moving average price of $113.06.

Natera (NASDAQ:NTRA) last posted its quarterly earnings results on Thursday, August 8th. The medical research company reported ($0.30) earnings per share for the quarter, beating the consensus estimate of ($0.69) by $0.39. Natera had a negative net margin of 21.47% and a negative return on equity of 36.74%. The firm had revenue of $413.35 million during the quarter, compared to the consensus estimate of $343.00 million. During the same period in the previous year, the firm posted ($0.97) earnings per share. The business’s revenue was up 58.1% compared to the same quarter last year. Analysts predict that Natera, Inc. will post -1.96 EPS for the current fiscal year.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.